mirror of
https://gitlab.com/upRootNutrition/obsidian.git
synced 2025-06-15 15:45:11 -05:00
34 lines
1.5 KiB
Markdown
34 lines
1.5 KiB
Markdown
|
https://pubmed.ncbi.nlm.nih.gov/32113648/
|
||
|
|
|
||
|
|
"Genetic evidence fails to support a cardioprotective role for apoA-I. This is in line with the cumulative evidence showing that HDL-related phenotypes are unlikely to have a protective role in CAD."
|
||
|
|
|
||
|
|
https://pubmed.ncbi.nlm.nih.gov/28847206/
|
||
|
|
|
||
|
|
"Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo."
|
||
|
|
|
||
|
|
https://pubmed.ncbi.nlm.nih.gov/17984165/
|
||
|
|
|
||
|
|
"Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition."
|
||
|
|
|
||
|
|
https://pubmed.ncbi.nlm.nih.gov/23126252/
|
||
|
|
|
||
|
|
"In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events."
|
||
|
|
|
||
|
|
https://pubmed.ncbi.nlm.nih.gov/28514624/
|
||
|
|
|
||
|
|
"Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease."
|
||
|
|
|
||
|
|
https://pubmed.ncbi.nlm.nih.gov/32203549/
|
||
|
|
|
||
|
|
#disease
|
||
|
|
#HDL
|
||
|
|
#HDLp
|
||
|
|
#LDL
|
||
|
|
#coronary_heart_disease
|
||
|
|
#cardiovascular_disease
|
||
|
|
#CETP_inhibitors
|
||
|
|
#ApoA1
|
||
|
|
#blood_lipids
|
||
|
|
#CETP_inhibitors
|
||
|
|
#lipidology
|